BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17825907)

  • 21. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
    Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
    Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
    Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
    Nishida H; Yoshimizu N; Ueno H; Fujita A; Kato T; Park JW; Yano T; Tobinai K; Ikeda Y
    Leuk Res; 2007 Mar; 31(3):417-8. PubMed ID: 16730062
    [No Abstract]   [Full Text] [Related]  

  • 26. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of primary non-Hodgkin lymphoma of the breast].
    Michetti M; Minelli M; Berni C; Bellini V; La Porta A; Manente L; Marinuzzi G; Antimi M
    Clin Ter; 1999; 150(4):307-10. PubMed ID: 10605170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic myeloid leukemia after chemotherapy treatment for non-Hodgkin's lymphoma].
    Sacanella E; Cervantes F; Navarro M; Terol MJ; Estruch R; Montserrat E; Rozman C
    Med Clin (Barc); 1992 Jun; 99(4):145-6. PubMed ID: 1635410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
    Bhagavathi S; Borromeo V; Desai H; Crisan D
    Ann Clin Lab Sci; 2008; 38(4):405-9. PubMed ID: 18988937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
    Buyukbayrak EE; Ergen B; Karsidag YK; Kars B; Turan C; Argon D
    Arch Gynecol Obstet; 2008 Aug; 278(2):161-3. PubMed ID: 18193246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
    Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
    Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
    Irvine DA; Shepherd JD
    Bone Marrow Transplant; 2009 Aug; 44(4):267-8. PubMed ID: 19234506
    [No Abstract]   [Full Text] [Related]  

  • 36. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
    Burke MJ; Willert J; Desai S; Kadota R
    Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
    Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.